文章核心观点 - 麦克森公司(McKesson)预计在2024年6月结束的季度中将实现收入同比增长,但利润同比下降[1][2][4] - 分析师预计麦克森公司的季度业绩可能会超出市场预期,从而推动股价上涨,反之则可能导致股价下跌[2][3] - 麦克森公司的实际业绩与预期的差异是影响其股价短期走势的关键因素[1] 根据相关目录分别进行总结 业绩预期 - 麦克森公司预计将在2024年8月7日公布季度业绩报告[2] - 分析师预计麦克森公司将实现每股7.16美元的季度盈利,同比下降1.5%;收入将达到832.1亿美元,同比增长11.7%[4] - 过去30天内,分析师对麦克森公司季度盈利预期上调了0.66%[5][6] 业绩超预期分析 - 麦克森公司的"最新预测"高于"共识预测",表明分析师最近对公司盈利前景持乐观态度,这导致其"预期惊喜指数"为正值[12][13] - 麦克森公司目前评级为"持有"(Zacks Rank 3),这种组合表明其很可能会超越共识盈利预期[13] - 过去4个季度,麦克森公司有3次超越了共识盈利预期[15] 行业内其他公司表现 - 另一家医疗-牙科用品行业公司亨利舍恩(Henry Schein)预计将在2024年6月季度实现每股1.26美元的盈利,同比下降3.8%;收入将达到32.8亿美元,同比增长5.7%[19] - 过去30天,亨利舍恩的共识盈利预期小幅上调0.1%,但其"预期惊喜指数"为负,加上评级为"卖出",这使其很难确定会超越共识盈利预期[20][21]

The most recent trading session ended with McKesson (MCK) standing at $600.16, reflecting a +0.74% shift from the previouse trading day's closing. This change lagged the S&P 500's 1.11% gain on the day. At the same time, the Dow added 1.64%, and the tech-heavy Nasdaq gained 1.03%.The prescription drug distributor's shares have seen an increase of 0.43% over the last month, surpassing the Medical sector's loss of 0.54% and the S&P 500's loss of 1.16%.Analysts and investors alike will be keeping a close eye o ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this prescription drug distributor have returned -1.6% over the past month versus the Zacks S&P 500 composite's -0.3% change. The Zacks Medical - Dental Supplies industry, to which McKesson belongs, has lost 1.1% over this period. Now the key question is: Where could the stock be headed in the near term?Whi ...

McKesson (MCK) is witnessing strong momentum, with its shares having rallied 26.1% year to date against 1.5% decline of the industry. The S&P 500 composite has risen 16.9% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments — Distribution Sol ...

McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a solid fourth-quarter fiscal 2024 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.Over the past year, this Zacks Rank #3 (Hold) stock has rallied 41.4%.The renowned health care services and information technology company has a market capitalization of ...

文章核心观点 - 公司在最新交易会话中收盘价为575.23美元,较前一交易日下跌1.98%,低于标普500指数0.88%的跌幅 [1] - 公司股价在过去一个月内上涨0.35%,优于医疗行业下跌1.09%,但低于标普500指数5.11%的涨幅 [2] - 公司预计将于2024年8月7日发布财报,预计每股收益为7.16美元,同比下降1.51%;预计收入为833.6亿美元,同比增长11.92% [3] - 全年来看,公司预计每股收益为31.47美元,同比增长14.69%;预计收入为3548亿美元,同比增长14.84% [4] - 分析师对公司的预测有所下调,但公司仍保持Zacks Rank 3(Hold)评级 [5][6][7] - 公司估值方面,其市盈率为18.65,高于行业平均水平17.91;PEG比率为1.38,低于行业平均1.96 [8][9] - 公司所属医疗-牙科用品行业目前在250多个行业中排名前35% [10][11]

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this prescription drug distributor have returned +7.3%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Alth ...

McKesson (MCK) closed the most recent trading day at $599.56, moving -0.8% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.49%. The prescription drug distributor's shares have seen an increase of 10.04% over the last month, surpassing the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%. Analysts and investors alike will be keeping a close eye on the perfor ...

In the latest market close, McKesson (MCK) reached $603.24, with a +0.05% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.77%, and the Nasdaq, a tech-heavy index, lost 0.79%. Coming into today, shares of the prescription drug distributor had gained 8.17% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%. The upcoming earnings release of McKesson will be of great interest to investors. ...

McKesson Corporation's (MCK) Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI (leuprolide) 42mg injection emulsion for subcutaneous use. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI was approved by the FDA on May 25, 2021. The availability of the FDA-appr ...